Form 4: Cryoport Director Exercises Options and Sells Shares Under Pre-Arranged Trading Plan

A director at Cryoport, Inc. executed a pre-planned transaction, exercising stock options and subsequently selling a portion of the acquired common stock.

Summary

• Ramkumar Mandalam, a Director at Cryoport, Inc. (CYRX), engaged in a pre-arranged trading plan on June 24, 2025.
• Mr. Mandalam exercised 20,000 stock options at an exercise price of $3.07 per share.
• Concurrently, he sold 13,321 shares of Cryoport common stock at a weighted average price of $7.015 per share, with prices ranging from $7.00 to $7.07.
• Following these transactions, Mr. Mandalam's direct beneficial ownership of common stock is 73,056 shares, and he holds 60,000 unexercised stock options.
• The transactions were conducted automatically pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly cautious. While the transactions were pre-planned under a 10b5-1 plan, a director selling shares can still be viewed with some skepticism by investors, even if it's for personal liquidity or diversification.

Positives

• The exercise of stock options at a lower price ($3.07) and subsequent sale at a higher price (weighted average $7.015) indicates a profitable transaction for the reporting person.
• The transactions were executed under a Rule 10b5-1 trading plan, which suggests the trades were pre-scheduled and not based on immediate, non-public information, potentially mitigating concerns about opportunistic insider selling.

Negatives

• A director selling shares, even under a pre-arranged plan, reduces their direct equity stake in the company, which some investors might interpret as a lack of conviction or a move to diversify.

Risks

• No specific risks to the company's operations or financial health are mentioned in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information relevant to broader industry trends or competitor analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe the director's reduction in direct equity ownership, which could influence their perception of insider confidence, though mitigated by the 10b5-1 plan.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request from Cryoport, Inc., any security holder, or the SEC staff.

Key Dates

Keywords

Cryoport, CYRX, Form 4, Insider Trading, Stock Options, Share Sale, Director, 10b5-1 Plan, Beneficial Ownership